Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma

BACKGROUND: Single arm phase 1 and 2 studies on Crizotinib in ALK-positive patients so far have shown rapid and durable responses. Spontaneous pneumothoraces as a result of response to anti-cancer therapy are rare in oncology but have been documented in a number of tumour types including lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Gennatas, Spyridon, Stanway, Susana J, Thomas, Robert, Min, Toon, Shah, Riyaz, O’Brien, Mary ER, Popat, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640977/
https://www.ncbi.nlm.nih.gov/pubmed/23617826
http://dx.doi.org/10.1186/1471-2407-13-207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640977/
https://www.ncbi.nlm.nih.gov/pubmed/23617826
http://dx.doi.org/10.1186/1471-2407-13-207

Ejemplares similares